-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
Community-acquired -X- _ O
pneumonia -X- _ O
( -X- _ O
CAP -X- _ O
) -X- _ O
account -X- _ O
for -X- _ O
a -X- _ O
high -X- _ O
proportion -X- _ O
of -X- _ O
ICU -X- _ O
admissions -X- _ O
, -X- _ O
with -X- _ O
Streptococcus -X- _ O
pneumoniae -X- _ O
being -X- _ O
the -X- _ O
main -X- _ O
pathogen -X- _ O
responsible -X- _ O
for -X- _ O
these -X- _ O
infections. -X- _ O
However -X- _ O
, -X- _ O
little -X- _ O
is -X- _ O
known -X- _ O
on -X- _ O
the -X- _ O
clinical -X- _ O
features -X- _ O
and -X- _ O
outcomes -X- _ O
of -X- _ O
ICU -X- _ B-Patient
patients -X- _ I-Patient
with -X- _ I-Patient
pneumococcal -X- _ I-Patient
pneumonia. -X- _ I-Patient
The -X- _ O
aims -X- _ O
of -X- _ O
this -X- _ O
study -X- _ O
were -X- _ O
to -X- _ O
provide -X- _ O
epidemiological -X- _ O
data -X- _ O
and -X- _ O
to -X- _ O
determine -X- _ O
risk -X- _ O
factors -X- _ O
of -X- _ O
mortality -X- _ B-Outcome
in -X- _ O
patients -X- _ B-Patient
admitted -X- _ I-Patient
to -X- _ I-Patient
ICU -X- _ I-Patient
for -X- _ I-Patient
severe -X- _ I-Patient
S. -X- _ I-Patient
pneumoniae -X- _ I-Patient
CAP. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
We -X- _ O
performed -X- _ O
a -X- _ O
retrospective -X- _ O
review -X- _ O
of -X- _ O
two -X- _ O
prospectively-acquired -X- _ O
multicentre -X- _ O
ICU -X- _ O
databases -X- _ O
( -X- _ O
2001-2008 -X- _ O
) -X- _ O
. -X- _ O
Patients -X- _ B-Patient
admitted -X- _ I-Patient
for -X- _ I-Patient
management -X- _ I-Patient
of -X- _ I-Patient
severe -X- _ I-Patient
pneumococcal -X- _ I-Patient
CAP -X- _ I-Patient
were -X- _ O
enrolled -X- _ O
if -X- _ O
they -X- _ O
met -X- _ O
the -X- _ O
2001 -X- _ O
American -X- _ O
Thoracic -X- _ O
Society -X- _ O
criteria -X- _ O
for -X- _ O
severe -X- _ O
pneumonia -X- _ O
, -X- _ O
had -X- _ O
life- -X- _ O
threatening -X- _ O
organ -X- _ O
failure -X- _ O
and -X- _ O
had -X- _ O
a -X- _ O
positive -X- _ O
microbiological -X- _ O
sample -X- _ O
for -X- _ O
S. -X- _ O
pneumoniae. -X- _ O
Patients -X- _ O
with -X- _ O
bronchitis -X- _ O
, -X- _ O
aspiration -X- _ O
pneumonia -X- _ O
or -X- _ O
with -X- _ O
non-pulmonary -X- _ O
pneumococcal -X- _ O
infections -X- _ O
were -X- _ O
excluded. -X- _ O
RESULTS -X- _ O
: -X- _ O
Two -X- _ B-Patient
hundred -X- _ I-Patient
and -X- _ I-Patient
twenty -X- _ I-Patient
two -X- _ I-Patient
patients -X- _ I-Patient
were -X- _ O
included -X- _ O
, -X- _ O
with -X- _ O
a -X- _ O
median -X- _ O
SAPS -X- _ O
II -X- _ O
score -X- _ O
reaching -X- _ O
47 -X- _ O
[ -X- _ O
36-64 -X- _ O
] -X- _ O
. -X- _ O
Acute -X- _ B-Outcome
respiratory -X- _ I-Outcome
failure -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
154 -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
septic -X- _ I-Outcome
shock -X- _ I-Outcome
( -X- _ I-Outcome
n -X- _ I-Outcome
= -X- _ I-Outcome
54 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
their -X- _ I-Outcome
most -X- _ I-Outcome
frequent -X- _ I-Outcome
causes -X- _ I-Outcome
of -X- _ I-Outcome
ICU -X- _ I-Outcome
admission. -X- _ I-Outcome
Septic -X- _ I-Outcome
shock -X- _ I-Outcome
occurred -X- _ I-Outcome
in -X- _ I-Outcome
170 -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
77 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
mechanical -X- _ I-Outcome
ventilation -X- _ I-Outcome
was -X- _ I-Outcome
required -X- _ I-Outcome
in -X- _ I-Outcome
186 -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
84 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
; -X- _ I-Outcome
renal -X- _ I-Outcome
replacement -X- _ I-Outcome
therapy -X- _ I-Outcome
was -X- _ I-Outcome
initiated -X- _ I-Outcome
in -X- _ I-Outcome
70 -X- _ I-Outcome
patients -X- _ I-Outcome
( -X- _ I-Outcome
32 -X- _ I-Outcome
% -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Bacteraemia -X- _ I-Outcome
was -X- _ I-Outcome
diagnosed -X- _ I-Outcome
in -X- _ I-Outcome
101 -X- _ I-Outcome
patients. -X- _ I-Outcome
The -X- _ I-Outcome
prevalence -X- _ I-Outcome
of -X- _ I-Outcome
S. -X- _ I-Outcome
pneumoniae -X- _ I-Outcome
strains -X- _ I-Outcome
with -X- _ I-Outcome
decreased -X- _ I-Outcome
susceptibility -X- _ I-Outcome
to -X- _ I-Outcome
penicillin -X- _ I-Outcome
was -X- _ I-Outcome
39.7 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
Although -X- _ I-Outcome
antibiotherapy -X- _ I-Outcome
was -X- _ I-Outcome
adequate -X- _ I-Outcome
in -X- _ I-Outcome
92.3 -X- _ I-Outcome
% -X- _ I-Outcome
of -X- _ I-Outcome
cases -X- _ I-Outcome
, -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
reached -X- _ I-Outcome
28.8 -X- _ I-Outcome
% -X- _ I-Outcome
. -X- _ I-Outcome
In -X- _ I-Outcome
multivariate -X- _ I-Outcome
analysis -X- _ I-Outcome
, -X- _ I-Outcome
independent -X- _ I-Outcome
risk -X- _ I-Outcome
factors -X- _ I-Outcome
for -X- _ I-Outcome
mortality -X- _ I-Outcome
were -X- _ I-Outcome
age -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
1.05 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
1.02-1.08 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
male -X- _ I-Outcome
sex -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
2.83 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
1.16-6.91 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
renal -X- _ I-Outcome
replacement -X- _ I-Outcome
therapy -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
3.78 -X- _ I-Outcome
( -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
: -X- _ I-Outcome
1.71-8.36 -X- _ I-Outcome
) -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Co- -X- _ I-Outcome
morbidities -X- _ I-Outcome
, -X- _ I-Outcome
macrolide -X- _ I-Outcome
administration -X- _ I-Outcome
, -X- _ I-Outcome
concomitant -X- _ I-Outcome
bacteremia -X- _ I-Outcome
or -X- _ I-Outcome
penicillin -X- _ I-Outcome
susceptibility -X- _ I-Outcome
did -X- _ I-Outcome
not -X- _ I-Outcome
influence -X- _ I-Outcome
outcome. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ O
ICU -X- _ O
, -X- _ O
mortality -X- _ B-Outcome
of -X- _ I-Outcome
pneumococcal -X- _ I-Outcome
CAP -X- _ I-Outcome
remains -X- _ I-Outcome
high -X- _ I-Outcome
despite -X- _ O
adequate -X- _ O
antimicrobial -X- _ O
treatment. -X- _ O
Baseline -X- _ O
demographic -X- _ O
data -X- _ O
and -X- _ O
renal -X- _ O
replacement -X- _ O
therapy -X- _ O
have -X- _ O
a -X- _ O
major -X- _ O
impact -X- _ O
on -X- _ O
adverse -X- _ O
outcome -X- _ O
. -X- _ O

